Haemonetics Reports Q2 2027 Growth Driven by Plasma and Blood Management Technologies
Haemonetics (HAE) reported strong second-quarter fiscal 2027 results, with net revenue reaching $358 million, a 9.3% increase year-over-year. The growth was primarily fueled by the Plasma and Blood Management Technologies segments, specifically through organic growth in Apheresis and MedSurg product lines. Adjusted EPS rose 6.3% to $1.35, supported by operational execution and a reduced share count. Reflecting increased visibility into customer commitments, the company raised its organic revenue guidance to a range of 6% to 9%. While gross margins improved due to tariff refunds, management lowered operating margin guidance slightly to account for manufacturing investments and inflationary pressures. Despite these costs, cash flow remains robust, with first-half free cash flow increasing 57% year-over-year.
Tickers: $HAE
Topics: blood management technologies eps beat organic revenue guidance plasma management revenue growth